In the latest look at clinical trial transparency, a new analysis found that only 26% of drug makers made results publicly available for all studies used to win approval for their medicines during a recent two-year period.
The total rose to 67% when examining trials that were conducted in patients for indications approved by the Food and Drug Administration. But just 58% of the trials met legal requirements for registering and disclosing results for drugs that were approved in 2016 and 2017. And 11% of the drugs did not have any trials for which results were legally required to be reported at the time of their approval.
Create a display name to comment
This name will appear with your comment